* AtriCure Inc ATRC.OQ ATRC.O is expected to show a rise in
quarterly revenue when it reports results on November 3.
* The Mason, Ohio-based company is expected to report a
25.4% increase in revenue to $68.677 million from $54.76 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for AtriCure Inc is for a
loss of 33 cents per share. For the same quarter last year, the
company reported a loss of 11 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for AtriCure Inc is
$94, about 17.6% above its last closing price of $77.50.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 302021 -0.34 -0.33 -0.36 Missed -7.5
Mar. 312021 -0.37 -0.37 -0.38 Missed -3.5
Dec. 312020 -0.27 -0.28 -0.28 Met 0.6
Sep. 302020 -0.32 -0.34 -0.11 Beat 67.6
Jun. -0.56 -0.57 -0.20 Beat 64.9
302020
Mar. 312020 -0.40 -0.41 -0.42 Missed -3.5
Dec. 312019 -0.41 -0.41 -0.42 Missed -1.2
Sep. 302019 -0.30 -0.27 -0.25 Beat 8.1
This summary was machine generated November 2 at 02:08 GMT. All
figures in US dollars unless otherwise stated